Anbogen Therapeutics, Inc. (TPEX:7784)

Market Cap	1.74B
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	187.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	213,297
Open	9.30
Previous Close	9.30
Day's Range	8.56 - 9.42
52-Week Range	8.35 - 22.45
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Anbogen Therapeutics

Anbogen Therapeutics, Inc. develops precision anti-cancer drugs and conducts research and development in oncology. The company develops precision oncology drugs, including clinical-stage assets such as ABT-101 for non-small cell lung cancer with HER2 exon20 insertion mutations and ABT-301 for metastatic colorectal cancer in combination with anti-PD-1 therapies. It conducts clinical trials to evaluate the safety, tolerability, and efficacy of its drug candidates, including combination therapies with immune checkpoint inhibitors. The company mana...

• Industry: Pharmaceutical Preparations
• Founded: 2019
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7784

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 3, 2026

Data Sources Report a data error